The board of directors of China Biotech Services Holdings Limited announced that, Shanghai Longyao Biotech Company Limited announced the results of the phase I clinical study ("Phase I Study") of LY007 Cellular Injection, a novel CD20-targeted autologous chimeric antigen receptor T cell therapy in patients with relapse/refractory B-cell non-Hodgkin lymphoma ("B-NHL"), at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in the form of poster presentation. Large B-cell lymphoma ("LBCL") is a common subtype of B-NHL, and the majority of patients can be cured by standard immunochemotherapy regimens. However, approximately 40% of patients still face relapse/refractory dilemmas after first-line treatment.

The Phase I Study was conducted to evaluate the safety and tolerability of LY007 Cellular In injection for the treatment of relapse/refractory B -NHL patients. The Phase I Study demonstrated that LY007 Cellular Injection was well tolerated at the dose levels up to 5.0 x 106 cells/kg and showed a favorable dose-response relationship for the treatment of relapse/Refractory B-NHL. LY007 Cellular Injection is expected to provide a new treatment option for LBCL patients.

As of 25 December 2023, 9 patients were treated with single LY007 Cellular Injection infusions at 3 dose levels with a median follow-up of 5.09 (range 0.92-18.10) months. 89% (8/9) of patients had extranodal involvement, 78% (7/9) had an International Prognostic Index (IPI) score of 2, 44% (4/9) had a maximum tumor length of 5 cm and two patients had a maximum tumor length of >8 cm.